A digital twin of glimepiride for personalized and stratified diabetes treatment
Open Access
- 8 October 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1686415
Abstract
Introduction: Optimizing glimepiride therapy for type 2 diabetes (T2DM) is challenged by pronounced inter-individual variability in pharmacokinetics.Methods: We developed a whole-body physiologically based pharmacokinetic (PBPK) model as a digital twin of glimepiride, enabling systematic evaluation of how patient-specific factors influence drug disposition. Using curated data from 20 clinical studies, the digital twin mechanistically simulates glimepiride’s absorption, distribution, metabolism, and excretion (ADME). It accounts for key determinants of variability including renal and hepatic function, CYP2C9 genotype, and bodyweight.Results: The model accurately reproduced observed pharmacokinetics and quantified these factors’ impact on drug exposure. Increased glimepiride exposure was predicted in individuals with hepatic dysfunction or specific CYP2C9 variants, highlighting substantial genetic and physiological effects.Discussion: This digital twin provides mechanistic insights into pharmacokinetic variability and serves as an in silico platform for exploring individualized dosing and patient stratification strategies, laying the foundation for clinical decision support tools to improve T2DM management.Keywords
All Related Versions
This publication has 54 references indexed in Scilit:
- Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese IndividualsClinical Pharmacokinetics, 2022
- Physiologically-based pharmacokinetic models: approaches for enabling personalized medicineJournal of Pharmacokinetics and Pharmacodynamics, 2016
- Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic ModelClinical Pharmacokinetics, 2014
- Evaluation of Pharmacokinetic Drug Interactions Between Gemigliptin (Dipeptidylpeptidase-4 Inhibitor) and Glimepiride (Sulfonylurea) in Healthy VolunteersDrugs in R&D, 2014
- Dose Linearity of Glimepiride in Healthy Human Egyptian VolunteersClinical Pharmacology in Drug Development, 2013
- Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjectsEuropean Journal of Clinical Pharmacology, 2011
- Bioequivalence and pharmacokinetic evaluation of two formulations of glimepiride 2 mg: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy chinese male volunteersClinical Therapeutics, 2010
- Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairmentDiabetologia, 1996
- Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhoticsHepatology, 1987
- Drug distribution in renal failureThe American Journal of Medicine, 1977